News & Updates

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), anlotinib plus pepulimab appears to significantly increase progression-free survival (PFS) and overall survival (OS) compared with sorafenib, as shown in the results of the phase III APOLLO study conducted in China.

At the Asia Vaccines and Antivirals Summit (AVAS) 2025 held in Bangkok, Thailand, two expert-led sessions provided valuable perspectives on the expanding role of oral antivirals in COVID-19 management. Dr Daniel Griffin, an infectious disease specialist and Clinical Instructor of Medicine at Columbia University, New York, US, focused on protecting high-risk populations through the timely use of antiviral therapy. Complementing this, Professor Ching-Tai Huang of Chang Gung University and Memorial Hospital in Taiwan offered practical guidance on clinical management strategies, including patient risk stratification and therapeutic selection.

The addition of granulocyte colony-stimulating factor (GCSF) to prednisolone results in improved steroid responsiveness and prolonged survival with fewer infections and new-onset complications among patients with severe alcohol-associated hepatitis (SAH), a study has shown.

Treatment with the bivalent fibroblast growth factor 21 (FGF21) analogue efruxifermin falls short of improving fibrosis in patients with compensated cirrhosis caused by metabolic dysfunction–associated steatohepatitis (MASH), according to a phase 2b study.

The long-acting, bivalent fibroblast growth factor 21 analogue efruxifermin reduced fibrosis at 96 weeks in patients with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (MASH) in the phase 2b SYMMETRY trial.

The addition of elebsiran, an investigational small interfering ribonucleic acid (siRNA), to pegylated interferon (PEG-IFN) alfa led to a higher rate of hepatitis B surface antigen (HBsAg) loss in patients with chronic HB virus (HBV) infection compared with PEG-IFN alfa alone, according to the ENSURE study presented at EASL 2025.

Findings from the phase III ELATIVE^® trial demonstrate that the peroxisome proliferator-activated receptor (PPAR) agonist elafibranor improves fatigue in individuals with primary biliary cholangitis (PBC), with limited correlation with pruritus.